{
    "nct_id": "NCT03568656",
    "official_title": "An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours.",
    "inclusion_criteria": "* Provision of consent\n* ECOG performance status 0-1\n* Assessable disease (by CT, MRI, bone scan or X-ray)\n* Adequate organ function\n* Highly effective contraception measures for duration of study\n\nAdditional inclusion criteria for mCRPC patients only:\n\n* Previously received abiraterone and/or enzalutamide (or equivalent anti-androgen), and docetaxel (unless ineligible or refused)\n* Progressive disease documented by one or more of the following:\n\n  * Biochemical progression defined as at least 2 stepwise increases in a series of any 3 PSA values\n  * Progression as defined by RECIST v1.1 guideline for assessment of malignant soft tissue disease.\n  * Progression defined as two or more new metastatic bone lesions confirmed on bone scan from a previous assessment\n* PSA at screening ≥2 μg/L\n* Serum testosterone concentration ≤50 ng/dL\n* Serum albumin >2.5 g/dL\n\nAdditional inclusion criteria for patients in CCS1477 plus abiraterone combination arm:\n\n* Patients must have previously progressed on abiraterone treatment\n* Patients whose last dose of abiraterone is greater than 6 months prior to start of study treatment will receive a 4-week run-in treatment with abiraterone to confirm refractoriness to abiraterone treatment\n\nAdditional inclusion criteria for patients in CCS1477 plus enzalutamide combination arm:\n\n* Patients must have previously progressed on enzalutamide treatment\n* Patients whose last dose of enzalutamide is greater than 6 months prior to start of study treatment will receive a 4-week run-in treatment with enzalutamide to confirm refractoriness to enzalutamide treatment\n\nAdditional inclusion criteria for patients in mutation arm:\n\n* Advanced solid tumour with identification of markers which may indicate potential for response to p300/CBP inhibition. Markers include loss of function mutations in CREBBP, EP300 or ARID1A, MYC gene amplifications or rearrangements and androgen receptor (AR) gene amplifications or over-expression.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Intervention with any chemotherapy, investigational agents or other anti-cancer drugs within 14 days or 5 half-lives of the first dose\n* Radiotherapy with a wide field of radiation or to more than 30% of the bone marrow within 4 weeks of the first dose of study treatment\n* Major surgical procedure or significant traumatic injury within 4 weeks of the first dose of study treatment\n* Strong inhibitors of CYP3A4 or CYP3A4 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment\n* Strong inducers of CYP3A4 within 4 weeks of the first dose of study treatment\n* Statins; patients should discontinue statins prior to starting study treatment\n* Any unresolved reversible toxicities from prior therapy >CTCAE grade 1 at the time of starting study treatment\n* Any evidence of severe or uncontrolled systemic diseases\n* Any known uncontrolled inter-current illness\n* QTcF prolongation (> 480 msec).\n* Primary brain tumours or known or suspected brain metastases.\n\nAdditional exclusion criteria for patients in CCS1477 plus abiraterone combination arm:\n\n* Clinically significant cardiac abnormalities\n\nAdditional exclusion criteria for patients in CCS1477 plus enzalutamide combination arm:\n\n* History of seizures or other predisposing factors\n* Use of substrates with a narrow therapeutic index metabolised by CYP2C9 or CYP2C19 within 2 weeks of the first dose of study treatment\n* Clinically significant cardiac abnormalities",
    "miscellaneous_criteria": ""
}